Author

Elizabeth Iannotti Buchbinder

Brigham and Women's HospitalORCID 0000-0002-7979-8953Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 3 Research Focus:cell type annotation· 3 Research Focus:differential expression· 3 Approach:experimental assay· 3 Organism:human· 3 Approach:statistical model· 2 Approach:benchmark study· 1 Research Focus:cancer & tumor microenvironment· 1

Frequent Co-Authors

David LiuiD· 3 shared Genevieve Marie BolandiD· 3 shared Aikaterini DedeiliaiD· 2 shared Emily J. RobitschekiD· 2 shared Giuseppe TarantinoiD· 2 shared Jiajia CheniD· 2 shared Jiekun YangiD· 2 shared M. KellisiD· 2 shared

Activity by Year

2024-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

David LiuORCID

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Genomic classification and immune profiling define mucosal melanoma

Yingxiao Shi, Priyanka Sharma, Jia‐Ren Lin, Aikaterini Dedeilia, Tuulia Vallius, Giuseppe Tarantino, Mariana Laura López, Michael P. Manos, Sonia Cohen, Aleigha R. Lawless, Madeline K. Roelofs, Shishir Mani Pant, Jiajia Chen, Rameen Beroukhim, Elizabeth Iannotti Buchbinder, , Genevieve Marie Boland

This study identifies genomic subtypes and immune features of mucosal melanoma, linking CD163+ macrophages to immune resistance and suggesting TIM-3 blockade as a therapeutic target.

bioRxiv · Oct 16, 2026 · PreprintCancer Biology

Immunogenic tumor mass dormancy as a driver of persistent residual lesions in immunotherapy-treated melanoma

Yingxiao Shi, Zoltan Maliga, Tuulia Vallius, Shishir Mani Pant, Roxanne J. Pelletier, Brigette Kobs, Priyanka Solanky, Yiwen He, Eliezer M. Van Allen, Sandro Santagata, Patrick Alexander Ott, Christine Guo Lian, Elizabeth Iannotti Buchbinder, David Liu, Peter Karl Sorger

This study shows that immunogenic tumor mass dormancy, not cell-level quiescence, persists in residual melanoma lesions after immunotherapy, with active tumor cells and immune interactions.

bioRxiv · Jun 27, 2026 · PreprintCancer Biology

Specific oncogene activation of the cell of origin in mucosal melanoma

Swathy Babu, Jiajia Chen, Chloé S. Baron, Kaiwen Sun, Emily J. Robitschek, Alicia M. McConnell, Constance Wu, Aikaterini Dedeilia, Moshe Sade-Feldman, Rodsy Modhurima, Michael P. Manos, Kevin Y. Chen, Anna M. Cox, Calvin G. Ludwig, M. Kellis, , Megan L. Insco

This study develops a zebrafish model of mucosal melanoma by activating an oncogene and inactivating tumor suppressors, revealing that internal melanocytes give rise to tumors with distinct transcriptional and chromatin features.

Nature Communications · Jul 22, 2025Peer-reviewedCancer Biology

Stratified analysis identifies HIF-2α as a therapeutic target for highly immune-infiltrated melanomas

Amy Y. Huang, Kelly P. Burke, Ryan M. Porter, Lynn Meiger, Peter R. Fatouros, Jiekun Yang, Emily J. Robitschek, Natalie I. Vokes, Cora A. Ricker, Valeria Rosado, Giuseppe Tarantino, Jiajia Chen, Tyler J. Aprati, Marc Glettig, Yiwen He, , David Liu

The paper identifies HIF-2α as a therapeutic target for immune-infiltrated melanomas through stratified analysis of clinical and molecular data.

bioRxiv · Oct 29, 2024 · PreprintCancer Biology